Gastrointestinal hormones in food intake control;Las hormonas gastrointestinales en el control de la ingesta de alimentos

Endocrinologia y Nutricion

Volumn 56, Issue 6, 2009, Pages 317-330

  Crespo, Mayte Álvarez ^a   González Matías, lucas C ^a   Lozano, Manuel Gil ^a   Paz, Soledad Fontans ^a   Pérez, Marina Romaní ^a   Gago, Eva Vigo ^a   Ferrer, Federico Mallo ^a  

^a UNIVERSITY OF VIGO   (Spain)

Author keywords

Appetite; CCK; Food intake control; Gastrointestinal hormones; Ghrelin; GIP; GLP 1; PP; PYY

Indexed keywords

CHOLECYSTOKININ; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; INSULIN; PEPTIDE YY; POLYPEPTIDE;

APPETITE; COMORBIDITY; DRUG MECHANISM; ENERGY BALANCE; FOOD INTAKE; HUMAN; NONHUMAN; OBESITY; REVIEW; SATIETY; THERAPY EFFECT;

CHOLECYSTOKININ; DIPEPTIDES; EATING; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONES; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; OXYNTOMODULIN; PANCREATIC POLYPEPTIDE;

EID: 68649109360     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/S1575-0922(09)71946-1     Document Type: Review

References (183)

1. Gao Q., and Horvath T.L. Neuronal control of energy homeostasis. FEBS Lett 582 (2008) 132-141
2. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994) 425-432
3. Nicolaïdis S. Prenatal imprinting of postnatal specific appetites and feeding behavior. Metabolism 57 Suppl 2 (2008) S22-S26
4. Cummings D.E., and Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 117 (2007) 13-23
5. Reeve Jr. J.R., Liddle R.A., McVey D.C., Vigna S.R., Solomon T.E., Keire D.A., et al. Identification of nonsulfated cholecystokinin-58 in canine intestinal extracts and its biological properties. Am J Physiol Gastrointest Liver Physiol 287 (2004) G326-G333
6. Wank S.A. Cholecystokinin receptors. Am J Physiol 269 (1995) G628-G646
7. Gibbs J., Young R.C., and Smith G.P. Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature 245 (1973) 323-325
8. Muurahainen N., Kissileff H.R., Derogatis A.J., and Pi-Sunyer F.X. Effects of cholecystokinin-octapeptide (CCK-8) on food intake and gastric emptying in man. Physiol Behav 44 (1988) 645-649
9. Gibbs J., Falasco J.D., and McHugh P.R. Cholecystokinin-decreased food intake in Rhesus monkeys. Am J Physiol 230 (1976) 15-18
10. Asin K.E., Gore Jr. P.A., Bednarz L., Holladay M., and Nadzan A.M. Effects of selective CCK receptor agonists on food intake after central or peripheral administration in rats. Brain Res 571 (1992) 169-174
11. Moran T.H., Baldessarini A.R., Salorio C.F., Lowery T., and Schwartz G.J. Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. Am J Physiol 272 (1997) R1245-R1251
12. Smith G.P., Jerome C., Cushin B.J., Eterno R., and Simansky K.J. Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. Science 213 (1981) 1036-1037
13. Moran T.H., Katz L.F., Plata-Salaman C.R., and Schwartz G.J. Disordered food intake and obesity in rats lacking cholecystokinin A receptors. Am J Physiol 274 (1998) R618-R625
14. Moran T.H., and Bi S. Hyperphagia and obesity in OLETF rats lacking CCK-1 receptors. Philos Trans R Soc Lond B Biol Sci 361 (2006) 1211-1218
15. Lieverse R.J., Jansen J.B., Masclee A.A., and Lamers C.B. Satiety effects of a physiological dose of cholecystokinin in humans. Gut 36 (1995) 176-179
16. Beglinger C., Degen L., Matzinger D., D'Amato M., and Drewe J. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Am J Physiol Regul Integr Comp Physiol 280 (2001) R1149-R1154
17. Meereis-Schwanke K., Klonowski-Stumpe H., Herberg L., and Niederau C. Long-term effects of CCK-agonist and -antagonist on food intake and body weight in Zucker lean and obese rats. Peptides 19 (1998) 291-299
18. West D.B., Fey D., and Woods S.C. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol 246 (1984) R776-R787
19. Jordan J., Greenway F.L., Leiter L.A., Li Z., Jacobson P., Murphy K., et al. Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther 83 (2008) 281-287
20. Crawley J.N., and Beinfeld M.C. Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 302 (1983) 703-706
21. Matson C.A., Reid D.F., and Ritter R.C. Daily CCK injection enhances reduction of body weight by chronic intracerebroventricular leptin infusion. Am J Physiol Regul Integr Comp Physiol 282 (2002) R1368-R1373
22. Matson C.A., Reid D.F., Cannon T.A., and Ritter R.C. Cholecystokinin and leptin act synergistically to reduce body weight. Am J Physiol Regul Integr Comp Physiol 278 (2000) R882-R890
23. Riedy C.A., Chavez M., Figlewicz D.P., and Woods S.C. Central insulin enhances sensitivity to cholecystokinin. Physiol Behav 58 (1995) 755-760
24. Kobelt P., Tebbe J.J., Tjandra I., Stengel A., Bae H.G., Andresen V., et al. CCK inhibits the orexigenic effect of peripheral ghrelin. Am J Physiol Regul Integr Comp Physiol 288 (2005) R751-R758
25. Deng X., Guarita D.R., Pedroso M.R., Kreiss C., Wood P.G., Sved A.F., et al. PYY inhibits CCK-stimulated pancreatic secretion through the area postrema in unanesthetized rats. Am J Physiol Regul Integr Comp Physiol 281 (2001) R645-R653
26. Degen L., Drewe J., Piccoli F., Gräni K., Oesch S., Bunea R., et al. Effect of CCK-1 receptor blockade on ghrelin and PYY secretion in men. Am J Physiol Regul Integr Comp Physiol 292 (2007) R1391-R1399
27. Baranowska B., Radzikowska M., Wasilewska-Dziubinska E., Roguski K., and Borowiec M. Disturbed release of gastrointestinal peptides in anorexia nervosa and in obesity. Diabetes Obes Metab 2 (2000) 99-103
28. Butler M.G., Carlson M.G., Schmidt D.E., Feurer I.D., and Thompson T. Plasma cholecystokinin levels in Prader-Willi syndrome and obese subjects. Am J Med Genet 95 (2000) 67-70
29. Tatemoto K., and Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 285 (1980) 417-418
30. Larhammar D. Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Regul Pept 65 (1996) 165-174
31. Ekblad E., and Sundler F. Distribution of pancreatic polypeptide and peptide YY. Peptides 23 (2002) 251-261
32. Grandt D., Schimiczek M., Beglinger C., Layer P., Goebell H., Eysselein V.E., et al. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 51 (1994) 151-159
33. Keire D.A., Bowers C.W., Solomon T.E., and Reeve Jr. J.R. Structure and receptor binding of PYY analogs. Peptides 23 (2002) 305-321
34. Essah P.A., Levy J.R., Sistrun S.N., Kelly S.M., and Nestler J.E. Effect of macronutrient composition on postprandial peptide YY levels. J Clin Endocrinol Metab 92 (2007) 4052-4055
35. Ueno H., Yamaguchi H., Mizuta M., and Nakazato M. The role of PYY in feeding regulation. Regul Pept 145 (2008) 12-16
36. Playford R.J., Domin J., Beacham J., Parmar K.B., Tatemoto K., Bloom S.R., et al. Preliminary report: role of peptide YY in defence against diarrhoea. Lancet 335 (1990) 1555-1557
37. Batterham R.L., Cowley M.A., Small C.J., Herzog H., Cohen M.A., Dakin C.L., et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418 (2002) 650-654
38. Koegler F.H., Enriori P.J., Billes S.K., Takahashi D.L., Martin M.S., Clark R.L., et al. Peptide YY(3-36) inhibits morning, but not evening, food intake and decreases body weight in rhesus macaques. Diabetes 54 (2005) 3198-3204
39. Batterham R.L., Cohen M.A., Ellis S.M., Le Roux C.W., Withers D.J., Frost G.S., et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349 (2003) 941-948
40. Sileno A.P., Brandt G.C., Spann B.M., and Quay S.C. Lower mean weight after 14 days intravenous administration peptide YY3-36 (PYY3-36) in rabbits. Int J Obes (Lond) 30 (2006) 68-72
41. Boey D., Lin S., Karl T., Baldock P., Lee N., Enriquez R., et al. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 49 (2006) 1360-1370
42. Abbott C.R., Monteiro M., Small C.J., Sajedi A., Smith K.L., Parkinson J.R., et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044 (2005) 127-131
43. Koda S., Date Y., Murakami N., Shimbara T., Hanada T., Toshinai K., et al. The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology 146 (2005) 2369-2375
44. Batterham R.L., Ffytche D.H., Rosenthal J.M., Zelaya F.O., Barker G.J., Withers D.J., et al. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature 450 (2007) 106-109
45. Sainsbury A., Schwarzer C., Couzens M., Fetissov S., Furtinger S., Jenkins A., et al. Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc Natl Acad Sci U S A 99 (2002) 8938-8943
46. Corp E.S., McQuade J., Krasnicki S., and Conze D.B. Feeding after fourth ventricular administration of neuropeptide Y receptor agonists in rats. Peptides 22 (2001) 493-499
47. Kanatani A., Mashiko S., Murai N., Sugimoto N., Ito J., Fukuroda T., et al. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology 141 (2000) 1011-1016
48. Le Roux C.W., Batterham R.L., Aylwin S.J., Patterson M., Borg C.M., Wynne K.J., et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147 (2006) 3-8
49. Goldstone A.P., Patterson M., Kalingag N., Ghatei M.A., Brynes A.E., Bloom S.R., et al. Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J Clin Endocrinol Metab 90 (2005) 2681-2690
50. Näslund E., Grybäck P., Hellström P.M., Jacobsson H., Holst J.J., Theodorsson E., et al. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 21 (1997) 387-392
51. Kimmel J.R., Hayden L.J., and Pollock H.G. Isolation and characterization of a new pancreatic polypeptide hormone. J Biol Chem 250 (1975) 9369-9376
52. Kojima S., Ueno N., Asakawa A., Sagiyama K., Naruo T., Mizuno S., et al. A role for pancreatic polypeptide in feeding and body weight regulation. Peptides 28 (2007) 459-463
53. Batterham R.L., Le Roux C.W., Cohen M.A., Park A.J., Ellis S.M., Patterson M., et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 88 (2003) 3989-3992
54. Berntson G.G., Zipf W.B., O'Dorisio T.M., Hoffman J.A., and Chance R.E. Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome. Peptides 14 (1993) 497-503
55. Asakawa A., Inui A., Yuzuriha H., Ueno N., Katsuura G., Fujimiya M., et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 124 (2003) 1325-1336
56. Ueno N., Inui A., Iwamoto M., Kaga T., Asakawa A., Okita M., et al. Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology 117 (1999) 1427-1432
57. Whitcomb D.C., Puccio A.M., Vigna S.R., Taylor I.L., and Hoffman G.E. Distribution of pancreatic polypeptide receptors in the rat brain. Brain Res 760 (1997) 137-149
58. Taylor I.L., Impicciatore M., Carter D.C., and Walsh J.H. Effect of atropine and vagotomy on pancreatic polypeptide response to a meal in dogs. Am J Physiol 235 (1978) E443-E447
59. Schwartz T.W., Holst J.J., Fahrenkrug J., Jensen S.L., Nielsen O.V., Rehfeld J.F., et al. Vagal, cholinergic regulation of pancreatic polypeptide secretion. J Clin Invest 61 (1978) 781-789
60. Campbell R.E., Smith M.S., Allen S.E., Grayson B.E., French-Mullen J.M., and Grove K.L. Orexin neurons express a functional pancreatic polypeptide Y4 receptor. J Neurosci 23 (2003) 1487-1497
61. Clark J.T., Kalra P.S., Crowley W.R., and Kalra S.P. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 115 (1984) 427-429
62. Kanatani A., Mashiko S., Murai N., Sugimoto N., Ito J., Fukuroda T., et al. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology 141 (2000) 1011-1016
63. Marsh D.J., Hollopeter G., Kafer K.E., and Palmiter R.D. Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med 4 (1998) 718-721
64. Fujimoto S., Inui A., Kiyota N., Seki W., Koide K., Takamiya S., et al. Increased cholecystokinin and pancreatic polypeptide responses to a fat-rich meal in patients with restrictive but not bulimic anorexia nervosa. Biol Psychiatry 41 (1997) 1068-1070
65. Lassmann V., Vague P., Vialettes B., and Simon M.C. Low plasma levels of pancreatic polypeptide in obesity. Diabetes 29 (1980) 428-430
66. Zipf W.B., O'Dorisio T.M., Cataland S., and Sotos J. Blunted pancreatic polypeptide responses in children with obesity of Prader-Willi syndrome. J Clin Endocrinol Metab 52 (1981) 1264-1266
67. Brown J.C., Mutt V., and Pederson R.A. Further purification of a polypeptide demonstrating enterogastrone activity. J Physiol 209 (1970) 57-64
68. Meier J.J., Gallwitz B., and Nauck M.A. Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus. BioDrugs 17 (2003) 93-102
69. Baggio L.L., and Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007) 2131-2157
70. Mentlein R., Gallwitz B., and Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214 (1993) 829-835
71. Nauck M.A., Bartels E., Orskov C., Ebert R., and Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76 (1993) 912-917
72. Tseng C.C., Kieffer T.J., Jarboe L.A., Usdin T.B., and Wolfe M.M. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucosedependent insulinotropic polypeptide receptor antagonist in the rat. J Clin Invest 98 (1996) 2440-2445
73. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., and Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91 (1993) 301-307
74. Tseng C.C., Boylan M.O., Jarboe L.A., Usdin T.B., and Wolfe M.M. Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats. Am J Physiol 270 (1996) E661-E666
75. Verdich C., Toubro S., Buemann B., Lysgård Madsen J., Juul Holst J., and Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety -effect of obesity and weight reduction. Int J Obes Relat Metab Disord 25 (2001) 1206-1214
76. Vozzo R., Baker B., Wittert G.A., Wishart J.M., Morris H., Horowitz M., et al. Glycemic, hormone, and appetite responses to monosaccharide ingestion in patients with type 2 diabetes. Metabolism 51 (2002) 949-957
77. Daousi C., Wilding J.P., Aditya S., Durham B.H., Cleator J., Pinkney J.H., et al. Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes. Clin Endocrinol (Oxf) (2008) Doi: 10.111/J.1365-2265. 03451
78. Yip R.G., Boylan M.O., Kieffer T.J., and Wolfe M.M. Functional GIP receptors are present on adipocytes. Endocrinology 139 (1998) 4004-4007
79. Oben J., Morgan L., Fletcher J., and Marks V. Effect of the enteropancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol 130 (1991) 267-272
80. Eckel R.H., Fujimoto W.Y., and Brunzell J.D. Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes. Diabetes 28 (1979) 1141-1142
81. Miyawaki K., Yamada Y., Ban N., Ihara Y., Tsukiyama K., Zhou H., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8 (2002) 738-742
82. Althage MC, Ford EL, Wang S, Tso P, Polonsky KS, Wice BM. Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J Biol Chem. 20087;283:18365-76.
83. Isken F., Pfeiffer A.F., Nogueiras R., Osterhoff M.A., Ristow M., Thorens B., et al. Deficiency of glucose-dependent insulinotropic polypeptide receptor prevents ovariectomy-induced obesity in mice. Am J Physiol Endocrinol Metab 295 (2008) E350-E355
84. McClean P.L., Irwin N., Cassidy R.S., Holst J.J., Gault V.A., and Flatt P.R. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab 293 (2007) E1746-E1755
85. McClean P.L., Irwin N., Hunter K., Gault V.A., and Flatt P.R. (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy. Br J Pharmacol 155 (2008) 690-701
86. Holst J.J. The physiology of glucagon-like peptide 1. Physiol Rev 87 (2007) 1409-1439
87. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M., Meeran K., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379 (1996) 69-72
88. Meeran K., O'Shea D., Edwards C.M., Turton M.D., Heath M.M., Gunn I., et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140 (1999) 244-250
89. Scrocchi L.A., Brown T.J., MaClusky N., Brubaker P.L., Auerbach A.B., Joyner A.L., et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2 (1996) 1254-1258
90. Murphy K.G., and Bloom S.R. Gut hormones in the control of appetite. Exp Physiol 89 (2004) 507-516
91. Flint A., Raben A., Astrup A., and Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101 (1998) 515-520
92. Verdich C., Flint A., Gutzwiller J.P., Näslund E., Beglinger C., Hellström P.M., et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86 (2001) 4382-4389
93. Näslund E., King N., Mansten S., Adner N., Holst J.J., Gutniak M., et al. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr 91 (2004) 439-446
94. Zander M., Madsbad S., Madsen J.L., and Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallelgroup study. Lancet 359 (2002) 824-830
95. Rocca A.S., and Brubaker P.L. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 140 (1999) 1687-1694
96. Baggio L.L., Huang Q., Brown T.J., and Drucker D.J. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127 (2004) 546-558
97. Yamamoto H., Kishi T., Lee C.E., Choi B.J., Fang H., Hollenberg A.N., et al. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 23 (2003) 2939-2946
98. Thiele T.E., Van Dijk G., Campfield L.A., Smith F.J., Burn P., Woods S.C., et al. Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am J Physiol 272 (1997) R726-R730
99. Lachey J.L., D'Alessio D.A., Rinaman L., Elmquist J.K., Drucker D.J., and Seeley R.J. The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. Endocrinology 146 (2005) 458-462
100. Nauck M.A., and Meier J.J. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 128 (2005) 135-148
101. Verdich C., Toubro S., Buemann B., Lysgård Madsen J., Juul Holst J., and Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety -effect of obesity and weight reduction. Int J Obes Relat Metab Disord 25 (2001) 1206-1214
102. Tomasik P.J., Sztefko K., and Starzyk J. Cholecystokinin, glucose dependent insulinotropic peptide and glucagon-like peptide 1 secretion in children with anorexia nervosa and simple obesity. J Pediatr Endocrinol Metab 17 (2004) 1623-1631
103. Kieffer T.J., McIntosh C.H., and Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 (1995) 3585-3596
104. Vilsbøll T., Zdravkovic M., Le-Thi T., Krarup T., Schmitz O., Courrèges J.P., et al. Liraglutide, a long-acting human glucagonlike peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30 (2007) 1608-1610
105. Madsbad S., Schmitz O., Ranstam J., Jakobsen G., and Matthews DR; NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, doubleblind, randomized, controlled trial. Diabetes Care 27 (2004) 1335-1342
106. Eng J., Kleinman W.A., Singh L., Singh G., and Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267 (1992) 7402-7405
107. Iltz J.L., Baker D.E., Setter S.M., and Keith Campbell R. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clin Ther 28 (2006) 652-665
108. Szayna M., Doyle M.E., Betkey J.A., Holloway H.W., Spencer R.G., Greig N.H., et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141 (2000) 1936-1941
109. Navarro M., Rodríguez de Fonseca F., Álvarez E., Chowen J.A., Zueco J.A., Gómez R., et al. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 67 (1996) 1982-1991
110. Scott K.A., and Moran T.H. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am J Physiol Regul Integr Comp Physiol 293 (2007) R983-R987
111. Al-Barazanji K.A., Arch J.R., Buckingham R.E., and Tadayyon M. Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats. Obes Res 8 (2000) 317-323
112. Pérez-Tilve D., González-Matías L., Alvarez-Crespo M., Leiras R., Tovar S., Diéguez C., et al. Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes 56 (2007) 143-151
113. Blonde L., Klein E.J., Han J., Zhang B., Mac S.M., Poon T.H., et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8 (2006) 436-447
114. Bataille D., Gespach C., Tatemoto K., Marie J.C., Coudray A.M., Rosselin G., et al. Bioactive enteroglucagon (oxyntomodulin): present knowledge on its chemical structure and its biological activities. Peptides 2 Suppl 2 (1981) 41-44
115. Bataille D., Tatemoto K., Gespach C., Jörnvall H., Rosselin G., and Mutt V. Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide. FEBS Lett 146 (1982) 79-86
116. Schepp W., Dehne K., Riedel T., Schmidtler J., Schaffer K., and Classen M. Oxyntomodulin: a cAMP-dependent stimulus of rat parietal cell function via the receptor for glucagon-like peptide-1 (7-36)NH2. Digestion 57 (1996) 398-405
117. Fehmann H.C., Jiang J., Schweinfurth J., Wheeler M.B., Boyd III A.E., and Göke B. Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39). Peptides 15 (1994) 453-456
118. Dakin C.L., Gunn I., Small C.J., Edwards C.M., Hay D.L., Smith D.M., et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology 142 (2001) 4244-4250
119. Le Quellec A., Kervran A., Blache P., Ciurana A.J., and Bataille D. Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastrone. J Clin Endocrinol Metab 74 (1992) 1405-1409
120. Druce M.R., and Bloom S.R. Oxyntomodulin: a novel potential treatment for obesity. Treat Endocrinol 5 (2006) 265-272
121. Schjoldager B., Mortensen P.E., Myhre J., Christiansen J., and Holst J.J. Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions. Dig Dis Sci 34 (1989) 1411-1419
122. Schjoldager B.T., Baldissera F.G., Mortensen P.E., Holst J.J., and Christiansen J. Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. Eur J Clin Invest 18 (1988) 499-503
123. Dakin C.L., Small C.J., Batterham R.L., Neary N.M., Cohen M.A., Patterson M., et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145 (2004) 2687-2695
124. Dakin C.L., Small C.J., Park A.J., Seth A., Ghatei M.A., and Bloom S.R. Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol Endocrinol Metab 283 (2002) E1173-E1177
125. Chaudhri O.B., Parkinson J.R., Kuo Y.T., Druce M.R., Herlihy A.H., Bell J.D., et al. Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. Biochem Biophys Res Commun 350 (2006) 298-306
126. Cohen M.A., Ellis S.M., Le Roux C.W., Batterham R.L., Park A., Patterson M., et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88 (2003) 4696-4701
127. Wynne K., Park A.J., Small C.J., Patterson M., Ellis S.M., Murphy K.G., et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54 (2005) 2390-2395
128. Sarson D.L., Scopinaro N., and Bloom S.R. Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity. Int J Obes 5 (1981) 471-480
129. Dubé P.E., and Brubaker P.L. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 293 (2007) E460-E465
130. Tsai C.H., Hill M., and Drucker D.J. Biological determinants of intestinotrophic properties of GLP-2 in vivo. Am J Physiol 272 (1997) G662-G668
131. Tang-Christensen M., Larsen P.J., Thulesen J., Rømer J., and Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 6 (2000) 802-807
132. Schmidt P.T., Näslund E., Grybäck P., Jacobsson H., Hartmann B., Holst J.J., et al. Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regul Pept 116 (2003) 21-25
133. Sørensen L.B., Flint A., Raben A., Hartmann B., Holst J.J., and Astrup A. No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int J Obes Relat Metab Disord 27 (2003) 450-456
134. Banasch M., Bulut K., Hagemann D., Schrader H., Holst J.J., Schmidt W.E., et al. Glucagon-like peptide 2 inhibits ghrelin secretion in humans. Regul Pept 137 (2006) 173-178
135. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 (1999) 656-660
136. Howard A.D., Feighner S.D., Cully D.F., Arena J.P., Liberator P.A., Rosenblum C.I., et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273 (1996) 974-977
137. Van der Lely A.J., Tschöp M., Heiman M.L., and Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 25 (2004) 426-457
138. Hosoda H., Kojima M., Matsuo H., and Kangawa K. Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 279 (2000) 909-913
139. Broglio F., Benso A., Gottero C., Prodam F., Gauna C., Filtri L., et al. Non-acylated ghrelin does not possess the pituitaric and pancreatic endocrine activity of acylated ghrelin in humans. J Endocrinol Invest 26 (2003) 192-196
140. Cummings D.E., Purnell J.Q., Frayo R.S., Schmidova K., Wisse B.E., and Weigle D.S. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50 (2001) 1714-1719
141. Tschöp M., Wawarta R., Riepl R.L., Friedrich S., Bidlingmaier M., Landgraf R., et al. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 24 (2001) RC19-RC21
142. Cummings D.E., Frayo R.S., Marmonier C., Aubert R., and Chapelot D. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues. Am J Physiol Endocrinol Metab 287 (2004) E297-E304
143. Sugino T., Yamaura J., Yamagishi M., Ogura A., Hayashi R., Kurose Y., et al. A transient surge of ghrelin secretion before feeding is modified by different feeding regimens in sheep. Biochem Biophys Res Commun 298 (2002) 785-788
144. Nakazato M., Murakami N., Date Y., Kojima M., Matsuo H., Kangawa K., et al. A role for ghrelin in the central regulation of feeding. Nature 409 (2001) 194-198
145. Wren A.M., Seal L.J., Cohen M.A., Brynes A.E., Frost G.S., Murphy K.G., et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86 (2001) 5992
146. Tschöp M., Smiley D.L., and Heiman M.L. Ghrelin induces adiposity in rodents. Nature 407 (2000) 908-913
147. Tschöp M., Weyer C., Tataranni P.A., Devanarayan V., Ravussin E., and Heiman M.L. Circulating ghrelin levels are decreased in human obesity. Diabetes 50 (2001) 707-709
148. Cummings D.E., Weigle D.S., Frayo R.S., Breen P.A., Ma M.K., Dellinger E.P., et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346 (2002) 1623-1630
149. English P.J., Ghatei M.A., Malik I.A., Bloom S.R., and Wilding J.P. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 87 (2002) 2984-2987
150. Otto B., Cuntz U., Fruehauf E., Wawarta R., Folwaczny C., Riepl R.L., et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 145 (2001) 669-673
151. Garcia J.M., Garcia-Touza M., Hijazi R.A., Taffet G., Epner D., Mann D., et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 90 (2005) 2920-2926
152. Cummings D.E., Clement K., Purnell J.Q., Vaisse C., Foster K.E., Frayo R.S., et al. Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med 8 (2002) 643-644
153. DelParigi A., Tschöp M., Heiman M.L., Salbe A.D., Vozarova B., Sell S.M., et al. High circulating ghrelin: a potential cause for hyperphagia and obesity in prader-willi syndrome. J Clin Endocrinol Metab 87 (2002) 5461-5464
154. Tan T.M., Vanderpump M., Khoo B., Patterson M., Ghatei M.A., and Goldstone A.P. Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome. J Clin Endocrinol Metab 89 (2004) 4162-4165
155. Tamura H., Kamegai J., Shimizu T., Ishii S., Sugihara H., and Oikawa S. Ghrelin stimulates GH but not food intake in arcuate nucleus ablated rats. Endocrinology 143 (2002) 3268-3275
156. Kamegai J., Tamura H., Shimizu T., Ishii S., Sugihara H., and Wakabayashi I. Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes 50 (2001) 2438-2443
157. Riediger T., Traebert M., Schmid H.A., Scheel C., Lutz T.A., and Scharrer E. Site-specific effects of ghrelin on the neuronal activity in the hypothalamic arcuate nucleus. Neurosci Lett 341 (2003) 151-155
158. Hewson A.K., and Dickson S.L. Systemic administration of ghrelin induces Fos and Egr-1 proteins in the hypothalamic arcuate nucleus of fasted and fed rats. J Neuroendocrinol 12 (2000) 1047-1049
159. Lawrence C.B., Snape A.C., Baudoin F.M., and Luckman S.M. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology 143 (2002) 155-162
160. Toshinai K., Date Y., Murakami N., Shimada M., Mondal M.S., Shimbara T., et al. Ghrelin-induced food intake is mediated via the orexin pathway. Endocrinology 144 (2003) 1506-1512
161. Chen H.Y., Trumbauer M.E., Chen A.S., Weingarth D.T., Adams J.R., Frazier E.G., et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 145 (2004) 2607-2612
162. Le Roux C.W., Neary N.M., Halsey T.J., Small C.J., Martinez-Isla A.M., Ghatei M.A., et al. Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. J Clin Endocrinol Metab 90 (2005) 4521-4524
163. Williams D.L., Grill H.J., Cummings D.E., and Kaplan J.M. Vagotomy dissociates short- and long-term controls of circulating ghrelin. Endocrinology 144 (2003) 5184-5187
164. Date Y., Murakami N., Toshinai K., Matsukura S., Niijima A., Matsuo H., et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123 (2002) 1120-1128
165. Sun Y., Ahmed S., and Smith R.G. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 23 (2003) 7973-7981
166. Wortley K.E., Del Rincon J.P., Murray J.D., Garcia K., Iida K., Thorner M.O., et al. Absence of ghrelin protects against earlyonset obesity. J Clin Invest 115 (2005) 3573-3578
167. Zigman J.M., Nakano Y., Coppari R., Balthasar N., Marcus J.N., Lee C.E., et al. Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 115 (2005) 3564-3572
168. Pfluger P.T., Kirchner H., Günnel S., Schrott B., Perez-Tilve D., Fu S., et al. Simultaneous deletion of ghrelin and its receptor increases motor activity and energy expenditure. Am J Physiol Gastrointest Liver Physiol 294 (2008) G610-G618
169. Asakawa A., Inui A., Kaga T., Katsuura G., Fujimiya M., Fujino M.A., et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 52 (2003) 947-952
170. Halem H.A., Taylor J.E., Dong J.Z., Shen Y., Datta R., Abizaid A., et al. A novel growth hormone secretagogue-1a receptor antagonist that blocks ghrelin-induced growth hormone secretion but induces increased body weight gain. Neuroendocrinology 81 (2005) 339-349
171. Zhang J.V., Ren P.G., Avsian-Kretchmer O., Luo C.W., Rauch R., Klein C., et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 310 (2005) 996-999
172. Bresciani E., Rapetti D., Donà F., Bulgarelli I., Tamiazzo L., Locatelli V., et al. Obestatin inhibits feeding but does not modulate GH and corticosterone secretion in the rat. J Endocrinol Invest 29 (2006) RC16-RC18
173. Lagaud G.J., Young A., Acena A., Morton M.F., Barrett T.D., and Shankley N.P. Obestatin reduces food intake and suppresses body weight gain in rodents. Biochem Biophys Res Commun 357 (2007) 264-269
174. Green B.D., Irwin N., and Flatt P.R. Direct and indirect effects of obestatin peptides on food intake and the regulation of glucose homeostasis and insulin secretion in mice. Peptides 28 (2007) 981-987
175. Nogueiras R., Pfluger P., Tovar S., Arnold M., Mitchell S., Morris A., et al. Effects of obestatin on energy balance and growth hormone secretion in rodents. Endocrinology 148 (2007) 21-26
176. Kobelt P., Wisser A.S., Stengel A., Goebel M., Bannert N., Gourcerol G., et al. Peripheral obestatin has no effect on feeding behavior and brain Fos expression in rodents. Peptides 29 (2008) 1018-1027
177. Seoane L.M., Al-Massadi O., Pazos Y., Pagotto U., and Casanueva F.F. Central obestatin administration does not modify either spontaneous or ghrelin-induced food intake in rats. J Endocrinol Invest 29 (2006) RC13-RC15
178. McKee K.K., Tan C.P., Palyha O.C., Liu J., Feighner S.D., Hreniuk D.L., et al. Cloning and characterization of two human G protein-coupled receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and neurotensin receptors. Genomics 46 (1997) 426-434
179. Holst B., Egerod K.L., Schild E., Vickers S.P., Cheetham S., Gerlach L.O., et al. GPR39 signaling is stimulated by zinc ions but not by obestatin. Endocrinology 148 (2007) 13-20
180. Lauwers E., Landuyt B., Arckens L., Schoofs L., and Luyten W. Obestatin does not activate orphan G protein-coupled receptor GPR39. Biochem Biophys Res Commun 351 (2006) 21-25
181. Tremblay F., Perreault M., Klaman L.D., Tobin J.F., Smith E., and Gimeno R.E. Normal food intake and body weight in mice lacking the G protein-coupled receptor GPR39. Endocrinology 148 (2007) 501-506
182. Nogueiras R., and Tschöp M. Biomedicine. Separation of conjoined hormones yields appetite rivals. Science 310 (2005) 985-986
183. Gourcerol G., St-Pierre D.H., and Taché Y. Lack of obestatin effects on food intake: should obestatin be renamed ghrelin-associated peptide (GAP)?. Regul Pept 141 (2007) 1-7